955 related articles for article (PubMed ID: 27311556)
1. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
4. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
Berger BM; Schroy PC; Dinh TA
Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
[TBL] [Abstract][Full Text] [Related]
5. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
7. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
8. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
[No Abstract] [Full Text] [Related]
9. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
Sharaf RN; Ladabaum U
Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
[TBL] [Abstract][Full Text] [Related]
10. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
12. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
13. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
14. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
15. Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening.
Kisiel JB; Fendrick AM; Ebner DW; Ozbay AB; Vahdat V; Estes C; Limburg PJ
J Med Econ; 2024; 27(1):746-753. PubMed ID: 38686394
[TBL] [Abstract][Full Text] [Related]
16. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People.
Redwood DG; Asay ED; Blake ID; Sacco PE; Christensen CM; Sacco FD; Tiesinga JJ; Devens ME; Alberts SR; Mahoney DW; Yab TC; Foote PH; Smyrk TC; Provost EM; Ahlquist DA
Mayo Clin Proc; 2016 Jan; 91(1):61-70. PubMed ID: 26520415
[TBL] [Abstract][Full Text] [Related]
17. A novel multitarget stool DNA test for colorectal cancer screening.
Malik P
Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
[TBL] [Abstract][Full Text] [Related]
18. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population.
Karlitz JJ; Fendrick AM; Bhatt J; Coronado GD; Jeyakumar S; Smith NJ; Plescia M; Brooks D; Limburg P; Lieberman D
Popul Health Manag; 2022 Jun; 25(3):343-351. PubMed ID: 34958279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]